se of Convalescent Plasma in the treatment of COVID-19
- Conditions
- COVID-19.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20200414047072N1
- Lead Sponsor
- Hilton Pharma Pvt. Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 357
Inclusion Criteria for Donors; Volunteer enrollment (Informed consent will be obtained; Annexures-2A & 2B).
All the regulations related to ICH-GCP and Blood Transfusion Authority (BTA) Pakistan will be followed.
Should fulfill all the criteria of a healthy blood donor (with the exception of history of COVID-19 during last 4-8 weeks.
History of COVID-19 during last 4-8 weeks.
RT-PCR negative for SARS-CoV-2 RNA (carried out on nasopharyngeal or oropharyngeal specimen).
Age cutoff: 18-55 years.
Body weight cut off: >50 kg for men and > 45 kg for women.
At least a week been passed since last use of glucocorticoids.
A minimum of 2-week duration been passed since complete recovery.
Inclusion Criteria for Recipients: Volunteer enrollment (Informed consent will be obtained; Annexures-3A & 3B).
Confirmed COVID-19 cases confirmed by RT-PCR laboratory tests.
Severe or Critical COVID-19 related features (8):
(a)Severe COVID-19, defined by the presence of any of the following features: i.Shortness of breath. ii.Respiratory rate = 30/min, iii. Arterial blood oxygen saturation = 93%, iv.Lung infiltrates > 50% within 24 to 48 hours
(b)Critical COVID-19, defined by the presence of any of the following features: i.Respiratory failure, ii.Shock iii.Multiple organ dysfunction
Allergy history for plasma, sodium citrate and methylene blue
For patients with history of autoimmune system diseases or selective IgA deficiency, the application of convalescent plasma should be evaluated cautiously by clinicians.
Patients having evidence of uncontrolled cytokine release syndrome leading to end-stage multi organ failure.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fever. Timepoint: registration day and week 4. Method of measurement: thermometer will be used for physical examination to check fever.;Resolution of infection. Timepoint: 28 days. Method of measurement: Two non-reactive Nucleic Acid Tests (NAT) for SARS-CoV-2 performed at an interval of at least 24 hours on nasopharyngeal swabs.;Lung infiltrates. Timepoint: registration day and week 4. Method of measurement: X-ray will be used.;Arterial blood oxygen saturation. Timepoint: registration day and week 4. Method of measurement: Lab test (blood from artery will used).;Respiratory rate. Timepoint: registration day and week 4. Method of measurement: physical examination was conducted to measure the breath rate by counting chest or abdomen rises number over a minute.
- Secondary Outcome Measures
Name Time Method